Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis.

Abrocitinib provides a valuable treatment option for patients with moderate-to-severe AD unresponsive to other therapies for those candidates without a high risk for significant adverse reaction associated with its use.